These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 36451831

  • 21. Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database.
    Lee M, Jeong K, Park YR, Rhee Y.
    Metabolism; 2023 Jan; 138():155311. PubMed ID: 36122764
    [Abstract] [Full Text] [Related]

  • 22. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
    Qiu JL, Luo SM, Yin WF, Li X, Zhou ZG.
    Zhonghua Yi Xue Za Zhi; 2023 Jan 07; 103(1):38-41. PubMed ID: 36594136
    [Abstract] [Full Text] [Related]

  • 23. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
    Liu Q, Yu Y, Lin J, Wang Y, Ai L, Li Q, Wu W, Jin H, Li S, Liu M, Yu S, Liu T.
    Eur J Cancer; 2021 Nov 07; 157():10-20. PubMed ID: 34464781
    [Abstract] [Full Text] [Related]

  • 24. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT, Niederer R, Wagner NB, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Joerger M, Risch M, Niederhauser C, Lenz TL, Früh M, Risch L, Semela D, Flatz L.
    J Cancer Res Clin Oncol; 2022 Mar 07; 148(3):647-656. PubMed ID: 34874490
    [Abstract] [Full Text] [Related]

  • 25. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X, Chen X, Wu X, Huang Y, Zhuang Y, Chen Y, Feng C, Lin X.
    J Endocrinol Invest; 2020 Oct 07; 43(10):1473-1483. PubMed ID: 32239475
    [Abstract] [Full Text] [Related]

  • 26. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies.
    Chen H, Zhang L, Zhao L, Li X.
    BMC Endocr Disord; 2023 Jul 06; 23(1):139. PubMed ID: 37415148
    [Abstract] [Full Text] [Related]

  • 27. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jul 06; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 28. Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.
    Inaba H, Kaido Y, Ito S, Hirobata T, Inoue G, Sugita T, Yamamoto Y, Jinnin M, Kimura H, Kobayashi T, Iwama S, Arima H, Matsuoka T.
    Endocrinol Metab (Seoul); 2022 Feb 06; 37(1):84-95. PubMed ID: 35255603
    [Abstract] [Full Text] [Related]

  • 29. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study.
    Hara N, Suwanai H, Yakou F, Ishii K, Iwasaki H, Abe H, Shikuma J, Sakai H, Miwa T, Suzuki R.
    Endocrine; 2023 Sep 06; 81(3):477-483. PubMed ID: 37178310
    [Abstract] [Full Text] [Related]

  • 30. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S, Hirokazu H, Yamagishi K, Hideki S, Masayuki E.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1697-1699. PubMed ID: 32592366
    [Abstract] [Full Text] [Related]

  • 31. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM.
    J Clin Endocrinol Metab; 2021 Aug 18; 106(9):e3704-e3713. PubMed ID: 33878162
    [Abstract] [Full Text] [Related]

  • 32. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.
    Liu J, Shi Y, Liu X, Zhang D, Zhang H, Chen M, Xu Y, Zhao J, Zhong W, Wang M.
    Transl Oncol; 2022 Oct 18; 24():101473. PubMed ID: 35905639
    [Abstract] [Full Text] [Related]

  • 33. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
    Byun DJ, Braunstein R, Flynn J, Zheng J, Lefkowitz RA, Kanbour S, Girotra M.
    Diabetes Care; 2020 Dec 18; 43(12):3106-3109. PubMed ID: 33051330
    [Abstract] [Full Text] [Related]

  • 34. Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review.
    Fang W, Gao Y, Shi X, Zhang X, Zhou S, Zhu H, Yan W, Wang H.
    Front Immunol; 2023 Dec 18; 14():1243773. PubMed ID: 37841238
    [Abstract] [Full Text] [Related]

  • 35. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS.
    Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X.
    J Endocrinol Invest; 2022 Nov 18; 45(11):2131-2137. PubMed ID: 35870109
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.
    Ogawa K, Kozuka Y, Uno H, Utsumi K, Noyori O, Hosoki R.
    Clin Drug Investig; 2021 Jul 18; 41(7):615-627. PubMed ID: 34110613
    [Abstract] [Full Text] [Related]

  • 38. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC, Tang Q, Yang KW, Mi Y, Fan Y, Yu W, Song Y, He ZS, Zhou LQ, Li XS.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug 18; 54(4):644-651. PubMed ID: 35950386
    [Abstract] [Full Text] [Related]

  • 39. Islet autoantibody positivity in an adult population with recently diagnosed diabetes in Uganda.
    Kibirige D, Sekitoleko I, Balungi P, Kyosiimire-Lugemwa J, Lumu W, Jones AG, Hattersley AT, Smeeth L, Nyirenda MJ.
    PLoS One; 2022 Aug 18; 17(5):e0268783. PubMed ID: 35604955
    [Abstract] [Full Text] [Related]

  • 40. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
    Zhu J, Luo M, Liang D, Gao S, Zheng Y, He Z, Zhao W, Yu X, Qiu K, Wu J.
    Int Immunopharmacol; 2022 Sep 18; 110():109053. PubMed ID: 35978507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.